Author: HUTCHMED (China) Limited

Posted Date:

April 8, 2026

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

HUTCHMED (China) Limited

April 8, 2026
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China

HUTCHMED (China) Limited

March 22, 2026
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China

HUTCHMED (China) Limited

March 9, 2026
Intended Retirement of Independent Non-executive Director and changes of composition of board committees

HUTCHMED (China) Limited

March 6, 2026
HUTCHMED Reports 2025 Full Year Results and Business Updates

HUTCHMED (China) Limited

March 5, 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

HUTCHMED (China) Limited

March 4, 2026
HUTCHMED to Announce 2025 Final Results

HUTCHMED (China) Limited

February 7, 2026